Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

M1 muscarinic receptor activation reduces the molecular pathology and slows the progression of prion-mediated neurodegenerative disease

Tools
- Tools
+ Tools

Dwomoh, Louis, Rossi, Mario, Scarpa, Miriam, Khajehali, Elham, Molloy, Colin, Herzyk, Pawel, Mistry, Shailesh N., Bottrill, Andrew R., Sexton, Patrick M., Christopoulos, Arthur, Conn, Jeffrey, Lindsley, Craig W., Bradley, Sophie J. and Tobin, Andrew B. (2022) M1 muscarinic receptor activation reduces the molecular pathology and slows the progression of prion-mediated neurodegenerative disease. Science Signaling, 15 (760). eabm3720. doi:10.1126/scisignal.abm3720 ISSN 1937-9145.

[img]
Preview
PDF
WRAP-M1-muscarinic-receptor-activation-reduces-molecular-pathology-slows-22.pdf - Accepted Version - Requires a PDF viewer.

Download (638Kb) | Preview
Official URL: https://doi.org/10.1126/scisignal.abm3720

Request Changes to record.

Abstract

Many dementias are propagated through the spread of “prion-like” misfolded proteins. This includes prion diseases themselves (such as Creutzfeldt-Jakob disease) and Alzheimer’s disease (AD), for which no treatments are available to slow or stop progression. The M 1 acetylcholine muscarinic receptor (M 1 receptor) is abundant in the brain, and its activity promotes cognitive function in preclinical models and in patients with AD. Here, we investigated whether activation of the M 1 receptor might slow the progression of neurodegeneration associated with prion-like misfolded protein in a mouse model of prion disease. Proteomic and transcriptomic analysis of the hippocampus revealed that this model had a molecular profile that was similar to that of human neurodegenerative diseases, including AD. Chronic enhancement of the activity of the M 1 receptor with the positive allosteric modulator (PAM) VU0486846 reduced the abundance of prion-induced molecular markers of neuroinflammation and mitochondrial dysregulation in the hippocampus and normalized the abundance of those associated with neurotransmission, including synaptic and postsynaptic signaling components. PAM treatment of prion-infected mice prolonged survival and maintained cognitive function. Thus, allosteric activation of M 1 receptors may reduce the severity of neurodegenerative diseases caused by the prion-like propagation of misfolded protein.

Item Type: Journal Article
Subjects: Q Science > QP Physiology
R Medicine > RC Internal medicine
Divisions: Faculty of Science, Engineering and Medicine > Science > Life Sciences (2010- )
SWORD Depositor: Library Publications Router
Library of Congress Subject Headings (LCSH): Muscarinic receptors , Nervous system -- Degeneration , Nervous system -- Degeneration -- Molecular aspect
Journal or Publication Title: Science Signaling
Publisher: American Association for the Advancement of Science (AAAS)
ISSN: 1937-9145
Official Date: 15 November 2022
Dates:
DateEvent
15 November 2022Published
Volume: 15
Number: 760
Article Number: eabm3720
DOI: 10.1126/scisignal.abm3720
Status: Peer Reviewed
Publication Status: Published
Reuse Statement (publisher, data, author rights): This is the author’s version of the work. It is posted here by permission of the AAAS for personal use, not for redistribution. The definitive version was published in Science Signaling on 15(760) https://doi.org/10.1126/scisignal.abm3720
Access rights to Published version: Open Access (Creative Commons)
Date of first compliant deposit: 9 December 2022
Date of first compliant Open Access: 9 December 2022
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
MR/P016693/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
Lord Kelvin Adam Smith FellowshipUniversity Of Glasgowhttp://dx.doi.org/10.13039/501100000853
MR/P019366/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
201529/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100010269
11554434National Health and Medical Research Councilhttp://dx.doi.org/10.13039/501100000925

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us